SS Innovations International Inc. Common Stock logo

SS Innovations International Inc. Common Stock(SSII)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$17.38
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SSII

11/13/2026: SSII (1-star) is currently NOT-A-BUY. Pass it for now.

SS Innovations International is a commercial-stage medical device company that develops cost-effective surgical robotic systems, notably the SSi Mantra. The company's primary strengths include rapid top-line revenue growth, highly modular system design, and pioneering tele-surgery capabilities that challenge high-cost legacy alternatives. Its core growth opportunity lies in expanding hospital installations globally and entering regulated Western markets. However, the company faces intense competition from entrenched industry leaders, ongoing operating cash burn, and execution risks. The stock suits growth-oriented investors willing to tolerate high volatility while monitoring regulatory milestones and liquidity management.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers rapid double-digit revenue expansion and substantial international market upside in surgical robotics.
Momentum investorStrong fit while signal remains positiveEpisodic news regarding regulatory milestones, installation surges, and global expansion can drive significant short-term stock momentum.
Value investorWeak fitThe company is currently unprofitable on a net income basis and trades on future growth potential rather than current earnings.
Dividend investorWeak fitSS Innovations pays no dividends, retaining all capital to fund corporate growth and product development.
Low-risk investorWeak fitHigh share price volatility, ongoing cash burn, and execution risks make the stock unsuitable for conservative capital preservation.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighAs a smaller-cap commercial-stage medical device stock, SSII experiences sharp price swings reacting to quarterly results and news flow.
Valuation riskMedium / highStock valuations depend heavily on multi-year growth expectations rather than current earnings or cash flows.
Competition risk (Intuitive Surgical and legacy medical device incumbents)HighCompeting against well-capitalized market leaders with deep hospital relationships creates severe barriers to rapid market capture.
Business qualityMediumProprietary technology and growing adoption highlight core product utility, though commercial scale is still developing.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskHighSuccessful scaling relies heavily on navigating complex international regulatory approvals and expanding global sales channels.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 332.81M USD
Price to earnings Ratio -
1Y Target Price 7
Price to earnings Ratio -
1Y Target Price 7
Volume (30-day avg) 93.1K shares
Beta 0.94
52 Weeks Range 1.26 - 6.79
Updated Date 11/13/2026
52 Weeks Range 1.26 - 6.79
Updated Date 11/13/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.06

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 21.61%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SSII receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SSII has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+36.7%) and strong revenue growth (+105.7%) are partially offset by weak cash generation (FCF margin -52.3%), weak profitability (net margin -28.5%).

Financial Health Rating

★★★★★
SSII's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 30.4%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is SSII's strongest growth driver at +105.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+36.7%, strong) is also strong, while free-cash-flow growth (-118.4%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.0% (soft) and 20.3% of outstanding shares are publicly tradable (soft). Insider ownership of 80.07% supports management-shareholder alignment.

Top 5 Institutional Investors

Hood River Capital Management LLC 0.42%
CWM Advisors, LLC 0.09%
Handelsbanken Fonder AB 0.06%
Eversept Partners, LP 0.05%
Jnba Financial Advisors Inc 0.05%

Unit Economics (Per $1K Revenue)

★★★★★
SSII generates approximately $460 of gross profit, $-193 of operating income, and $-523 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -48.60% (Tax Credit)

Quantitative Style Profile

★★★★★
SSII has a Value-Oriented profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Surgical Systems Capital SalesDirect sales and distribution of the SSi Mantra robotic console and patient-side carts to hospitals and medical centers.This is the primary upfront revenue driver when a new hospital adopts the robotic platform.
Instruments and Accessories (SSi Mudra)Recurring sales of proprietary single-use and reusable surgical instrument tips, staplers, energy devices, and sterile drapes.Provides a high-margin, recurring revenue stream as procedures are performed over time.
Service and Maintenance ContractsAnnual maintenance contracts, technical support, 24/7 system monitoring, and training modules.Ensures steady, predictable service revenue after initial system installation.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 267.87M
Price to Sales(TTM) 6.35
Enterprise Value 267.87M
Price to Sales(TTM) 6.35
Enterprise Value to Revenue 5.11
Enterprise Value to EBITDA -24.73
Shares Outstanding 200.49M
Shares Floating 40.67M
Shares Outstanding 200.49M
Shares Floating 40.67M
Percent Insiders 80.07
Percent Institutions 1.02

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.